Amyris, a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, sold its Vitamin E royalty agreement to Koninklijke DSM N.V. (Royal DSM). This agreement assigns Amyris’s rights to Vitamin E royalties to DSM in exchange for total consideration of approximately $57 million. In addition, DSM and Amyris have agreed to a further manufacturing cooperation for Amyris products at DSM’s Brotas facility that provides additional capacity and lower cost of goods sold with an expected approximate aggregate benefit of $30–$40 million over the next three years. The expected economic benefit of both agreements to Amyris is approximately $90 million.
IL BIOECONOMISTA 